BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

9 articles for MD Walkinshaw

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of ML251, a Potent Inhibitor of T. brucei and T. cruzi Phosphofructokinase.EBI
National Center For Advancing Translational Sciences
Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.EBI
Palacky£? University and Institute of Experimental Botany Ascr
Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis.EBI
University of Edinburgh
Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation.EBI
University of Nottingham
Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31.EBI
University of Glasgow
Hydrophobically tagged janus kinase inhibitors and uses thereofBDB
Dana-Farber Cancer Institute
Kinase inhibitorsBDB
Topivert Pharma
Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold.BDB
Merck Serono
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.BDB
Upjohn